AB Science
Description AB Science S.A., a pharmaceutical company, engages in the discovery, development, and commercialization of protein kinase inhibitors for use in human and veterinary medicine in the United States and Europe. The company focuses on therapies for the treatment of cancer, inflammatory diseases, and central nervous system diseases. Its lead compound is Masitinib, a tyrosine kinase inhibitor that targets mast cells and selected kinases, including c-Kit, PDGR, and Lyn. The companys pipeline includes three Phase III clinical trials ongoing in pancreatic cancer, GIST, and mastocytosis and eight Phase II clinical trials completed. It markets Masitinib under the brand name Masivet for the veterinary market in Europe. The companys other tyrosine kinase inhibitors that plan to initiate preclinical development include KIT816 for aggressive mastocytosis, seminoma, and acute myeloid leukemia; VEGFR2 for kidney cancer; and Bcr-Abl/Lyn for chronic myeloid leukemia. AB Science S.A. was founded in 2001 and is headquartered in Paris, France. To view the detailed information, you need to SUBSCRIBE with us. |
 |